Goldman Sachs shareholders approve hefty executive pay packages despite criticism over lack of performance-based metrics.
Roche reports strong Q1 sales, driven by newer medicines, and confirms FY25 outlook despite challenges in Diagnostics Division.
Zelenskyy faces pressure to accept a peace deal involving territorial concessions, as the White House criticizes his 'megaphone diplomacy' and warns of potential loss of U.S. support.
Goldman Sachs shareholders approve hefty executive pay packages despite criticism over lack of performance-based metrics.
Roche reports strong Q1 sales, driven by newer medicines, and confirms FY25 outlook despite challenges in Diagnostics Division.
Zelenskyy faces pressure to accept a peace deal involving territorial concessions, as the White House criticizes his 'megaphone diplomacy' and warns of potential loss of U.S. support.